

Making Headway

Population Health Improvement with DRVS

PRESENTED BY:

Dr. Annemarie Witmer

Chief Health Services Officer
Central North Alabama Health
Services

Jaime DiFalco

Quality Improvement
Coordinator
Pendleton Community Care

Jessica Daily Haas

Director of Clinical Transformation
West Virginia Primary Care
Association



azara2024
USER CONFERENCE APR 30–MAY 2 | BOSTON, MA

Today's Presenters



Dr. Annemarie Witmer
Central North Alabama
Health Services




Jessica Daily Haas
West Virginia Primary Care
Association (WVPCA)



Jamie DiFalco
Pendleton Community Care

Agenda



HYPERTENSION AND QUALITY INITIATIVES

Dr. Annmarie Witmer | Central North Alabama Health Services, Inc.



GOING FOR THE CUP! USING DRVS FOR IMPROVEMENT IN DIABETIC OUTCOMES

Jessica Daily Haas | WVPCA

Jamie DiFalco | Pendleton Community Care



QUESTIONS

Azara Annual Conference 2024

Hypertension and Quality Initiatives



Dr. Annmarie Witmer, MSN, MSHA, DNP,
CRNP

Clinical Services Officer
Central North Alabama Health
Services, Inc.



Central North Alabama Health Services, Inc.

Your Health, Our Mission



1982

Incorporated as a 2-physician family practice in North Alabama.



16,000

Patients served in 2022




98%

Patients at or below 200% of the FPL



50%

Patients uninsured



27%

Patients with a diagnosis of hypertension



1st & 2nd

Quartile performance for more than half of CQMs



Patients with Low Income and Poverty Levels in our Clinics

Clinics	% Poverty	% Low income
Huntsville	27%	51%
Athens	23%	41%
New Market	9%	30%
Toney	9%	30%



Population served by Health Centers

82%

Live at or people FPL, compared
to 11.5% nationally



28%

Are without health insurance,
compared to 19% nationally



35%

Have Medicaid coverage,
compared to 50% nationally



Alabama

7th

poorest state

3rd

poorest health outcomes

2nd


lowest life expectancy

1st

highest level of mortality related to CVD
and stroke

1st

highest level of mortality for heart disease



Hypertension in Alabama

**Heart disease is the
leading cause of
death in Alabama.**

**15,173 deaths
from heart
disease in 2022**



Hypertension in CNAHSI



Hypertension is the leading monthly diagnosis across CNAHSI from 2019 to date



3,423 patients 18-45 with HTN in 2019



53.19% BP Control rate in 2019



Patients routinely ran out of meds




Had no way to check blood pressure, so if they had no symptoms, they did not consider it a priority




Hypertension in CNAHSI


In 2021 received HRSA HTN Grant to:



- Conduct outreach and engage patients with HTN
- Provide patient education




- Purchase Bluetooth and wireless-enabled SMBP devices
- Implement clinical processes that support use of SMBP devices
- Develop case management to support engagement and use of SMBP device




- Train for staff on new workflows
- Contract with Chronic Care IQ Care Management Platform for Remote Patient Monitoring in Q4 2021

Hypertension Grant Work



Enabling Services Case Managers did **education for staff** on the importance of proper **blood pressure technique**



Developed **hypertension protocols** to assist in case management




Developed **patient education booklet** with tips on properly taking blood pressure, diet, exercise, and logs for patient to complete and bring to health visits



Case managers **prioritized the stage 2 uncontrolled patients** placed on Remote Patient Monitoring (RPM) at the beginning



UDS HTN Performance



Numbers in the EMR were anywhere from 6% to 40% different from the Azara numbers.

Mapping was the key to the difference - Azara pulled from the entire patient record, not just one specific area.



Creating Data Driven Change

implemented in 2022



PVP

Leveraged the Patient Visit Planning report to support pre-visit planning

Visit Reason: Hypertension 3m f/u			
Phone: Lang: English Risk: Low (8)	Portal Access: N Cohorts: Dyn - Uncontrolled HTN, Hypertension	PCP: Payer: SLIDING FEE SCHEDULE - DISCOUNT CM: Unassigned	
ALERT	MESSAGE	DATE	RESULT
Mammo	Missing		
Pap HPV	Missing		
LDL	Overdue	12/16/2022	74
BP	Out of Range	1/22/2024	140/94
Hypertension Medication Intensification	Missing		

AMA MAP™ measures, reports, and dashboards, used to track process and outcome improvements


AMA MAP™ Hypertension

AMA MAP BP™ Metric Measures ⓘ		
REPORT		
MEASURE	RESULT	TARGET
ⓘ AMA MAP BP™ - HTN-Repeat Blood Pressure Measurement	27.7%	50.0%
ⓘ AMA MAP BP™ - HTN-Follow-Up After Visit with Uncontrolled HTN	13.1%	50.0%
ⓘ AMA MAP BP™ - HTN-Medication Intensification	20.8%	30.0%
ⓘ Hypertension Controlling High Blood Pressure (CMS 165v10)	53.7%	70.0%
ⓘ HTN-Improvement in Blood Pressure (CMS 65v8)	12.6%	Not Set

Continued Hypertension Initiatives



Alabama Cardiovascular Cooperative Heart Health Improvement Project



The project concentrated on:



Patients who were not enrolled in
the RPM program




Staff understanding and
engagement



Focus on patient education, lifestyle changes,
medication adherence, medication intensification, self-
management goals, and patient follow up



Baseline Data (08/01/21 – 07/31/22) Controlled HTN (CMS 165)



Alabama Cardiovascular Cooperative (ALCC)



Heart Health Improvement Project (HHIP)

Funded by Agency for Healthcare Research and Quality (AHRQ)



Tools for Success:

- Practice Facilitation & Technical Assistance
- Data Transparency
- Onsite & e-Learning




Commitments:

- Assign Practice Champion for each clinic location
- Monthly in-person and/or virtual meetings over the course of one year
- Complete one PDSA per quarter




Four Domains




Self-Management Support

Implementation of self-management goals for all qualifying HTN patients (18 – 85 with pre-HTN or HTN) that were not enrolled in the Remote Patient Monitoring (RPM) program



Standardized Care Processes

Implementation of the Hill-Bone BP Compliance Scale for all patients presenting for an appointment with a known diagnosis of HTN



Team Engagement, Optimized Care, & Outreach

Standardization (and implementation where necessary) of daily patient-centered huddles to include all members of the care team




Clinical Information Systems


Use of AMA MAP™ resources in DRVS to target repeat blood pressure measurement and medication intensification



Self Management Support




Team Engagement, Optimized Care, & Outreach




Standardize Care Processes




Standardize Care Processes



AMA MAP BP Dashboard - Organization



AMA MAP BP Dashboard – Clinic Level



Medication Intensification Provider Targeting

AMA MAP BP™ - HTN-Medication Intensification

MEASURE

PERIOD

TY March 2024

RENDERING PROVIDERS

All Rendering Provid...

All

Gaps

Num

Excl

SAVED COLUMNS

NUMERATOR	EXCLUSION	DATE	PROVIDER	TYPE	REASON	HTN	
	N	3/26/2024	WITMER, ANNEMARIE	HFHC - Adult Medicine	Hypertension	3m f/u	11/26/2018
	N	3/26/2024	WITMER, ANNEMARIE	HFHC - Adult Medicine	Hypertension	3m f/u	11/26/2018
	N	3/26/2024	WITMER, ANNEMARIE	HFHC - Adult Medicine	Hypertension	Hypertension	3/5/2019
	N	3/26/2024	WITMER, ANNEMARIE	HFHC - Adult Medicine	Hypertension	Hypertension	3/5/2019
	N	3/26/2024	WITMER, ANNEMARIE	HFHC - Adult Medicine	Hypertension	Hypertension	3/5/2019
	N	3/26/2024	WITMER, ANNEMARIE	HFHC - Adult Medicine	Hypertension	Hypertension	3/5/2019
	N	3/26/2024	WITMER, ANNEMARIE	HFHC - Adult Medicine	Hyperlipidemia	f/up- Hyperlipidemia	11/3/2016
	N	3/26/2024	WITMER, ANNEMARIE	HFHC - Adult Medicine	Hyperlipidemia	f/up- Hyperlipidemia	11/3/2016
	N	3/26/2024	WITMER, ANNEMARIE	HFHC - Adult Medicine	Hypertension	Hypertension	3/5/2019
	N	3/26/2024	WITMER, ANNEMARIE	HFHC - Adult Medicine	Hypertension	Hypertension	3/5/2019

NEXT APPOINTMENT

In range


03/25/2024

03/31/2024

Clear

Year over Year Improvement

HTN Controlling High Blood Pressure



GROUPING

No Grouping

TARGETS

Primary

Secondary

Not Met

REPORT FORMAT

Scorecard

MEASURE	RESULT	CHANGE	TARGET	NUMERATOR	DENOMINATOR	EXCLUSIONS	GAP	TO TARGET	
<div></div> AMA MAP BP™ - HTN-Repeat Blood Pressure Measurement	26.6%	+ 15.1% ▲	50.0%	1,447	5,435	50	3,988	1,271	↓
<div></div> AMA MAP BP™ - HTN-Follow-Up After Visit with Uncontrolled HTN	10.3%	- 1.5% ▼	50.0%	243	2,369	20	2,126	942	↓
<div></div> AMA MAP BP™ - HTN-Medication Intensification	20.2%	+ 1.6% ▲	30.0%	1,027	5,075	46	4,048	496	↓
<div></div> Hypertension Controlling High Blood Pressure (CMS 165v10)	53.5%	+ 9.3% ▲	70.0%	1,706	3,188	70	1,482	526	↓
<div></div> HTN-Improvement in Blood Pressure (CMS 65v8)	19.2%	+ 1.1% ▲	Not Set	175	912	12	737		↓



PERIOD

TY January 2024

RENDERING PROVIDERS

All Rendering Provid...

BASELINE PERIOD

TY March 2023

+ Add Filter

Update

GROUPING

No Grouping

TARGETS

Primary

Secondary

Not Met

REPORT FORMAT

Scorecard

MEASURE	RESULT	CHANGE	TARGET	NUMERATOR	DENOMINATOR	
<div>Adults with HTN Prescribed a Guideline Recommended Therapy</div>	71.0%	+ 71.0% ▲	Not Set	2,590	3,648	↓
<div>AMA MAP BP™ - HTN-Average Systolic BP Change After Medication Intensification</div>	-1341.9	- 172.6% ▼	Not Set	-9,809	731	↓
<div>AMA MAP BP™ - HTN-Medication Intensification</div>	20.2%	+ 1.6% ▲	30.0%	1,027	5,075	↓
<div>Uncontrolled HTN on Monotherapy</div>	21.3%	- 5.2% ▼	Not Set	317	1,485	↓
<div>Uncontrolled HTN on No Anti-HTN Medications</div>	8.9%	- 1.8% ▼	Not Set	132	1,485	↓
<div>Uncontrolled HTN Prescribed a Guideline Recommended Therapy</div>	78.6%	+ 15.4% ▲	Not Set	1,167	1,485	↓



Abbreviations

ABPM: ambulatory blood pressure monitoring
ACEI: **angiotensin-converting enzyme** inhibitor
ARB: angiotensin receptor antagonist
ASCVD: atherosclerotic cardiovascular disease
BB: β -blocker
CCB: calcium channel blocker
DBP: diastolic blood pressure
HBPM: home blood pressure monitoring
NSAID: nonsteroidal anti-inflammatory drug
SBP: systolic blood pressure

HTN is defined by JNC 8 as:

Age <60 years: SBP ≥ 140 mm Hg and/or DBP ≥ 90 mm Hg at ≥ 2 visits
Age ≥ 60 years: SBP ≥ 150 mm Hg and/or DBP ≥ 90 mm Hg at ≥ 2 visits
With **diabetes** or **chronic kidney disease** (CKD): SBP ≥ 140 mm Hg and/or DBP ≥ 90 mm Hg

Goal BP

Age <60 years: SBP <140 mm Hg and DBP <90 mm Hg (for HBPM <135/85 mm Hg)
Age ≥ 60 years: SBP <150 mm Hg and DBP <90 mm Hg (for HBPM <140/90 mm Hg)
Age ≥ 60 years with CKD or **diabetes**: SBP <140 mm Hg and DBP <90 mm Hg (for HBPM <135/85 mm Hg)

Note: BP assessment should be based on an average of at least two readings measured on two or more separate occasions and confirmed in the outpatient setting with multiple readings.

Patients must be instructed to sit quietly in a chair, with feet on the floor and back supported for 5 minutes prior to taking BP.

Consider using HBPM or ABPM to evaluate for white coat hypertension when SBP >130 and <160 mm Hg or DBP >80 and <100 mm Hg.

*ASCVD Risk Estimator Plus

Available online at:
<https://tools.acc.org/ASCVD-risk-estimator-plus>

Start lifestyle modifications and determine ASCVD risk.*

Weight loss
Healthy diet
Reduced intake of dietary **sodium** (especially processed foods)
Enhanced intake of dietary **potassium**
Aerobic exercise (20 minutes, 4 days/week)
Limit alcohol (female ≤ 1 glass a day, male ≤ 2 glasses a day).
Smoking cessation
Limit NSAID use.

If BP 130–139/80–89 mm Hg

Trial of lifestyle modifications for 3–6 months before reevaluating BP and determining need for pharmacologic therapy

Stage 1 hypertension with either clinical ASCVD or 10-year ASCVD risk $\geq 10\%$?

No

No

Yes

Yes

Start pharmacologic treatment.

**Secondary causes of hypertension


CKD
Renovascular disease
Primary aldosteronism
Obstructive sleep apnea
Drug (especially NSAIDs), **caffeine**, or alcohol-induced hypertension
Pheochromocytoma
Cushing syndrome
Congenital adrenal hyperplasia
Hyperthyroidism or hypothyroidism
Aortic coarctation

Labs and diagnostics

Fasting blood glucose
Complete blood cell count
Lipids
Basic metabolic panel
Thyroid stimulating hormone
Urinalysis
Ophthalmologic evaluation
Electrocardiogram
Uric acid
Urinary **albumin**-to-creatinine ratio



Central North Alabama Health Services, Inc.



M**Measure
Accurately****A****Act
Rapidly****P****Partner with
Patients****Evidence-Based
Strategy**

- Obtain accurate, representative BPs to diagnose hypertension & assess control

- Initiate & intensify Rx for patients with uncontrolled BP

- Engage patients in self-management of hypertension

Action Steps

- Validated, automated devices
- Preparation & positioning
- Repeat BP measurement

- Combination Rx, single pill combinations (SPCs) preferred
- Rx protocol

- Follow up
- Collaborative communication
- Medication & lifestyle adherence
- SMBP

Process Metrics

- Confirmatory BP (repeat BP if first value high)

- Intensify Rx when BP uncontrolled

- Monthly follow-up for uncontrolled BP
- ≥ 10 mm Hg SBP fall after treatment intensification

Outcome Metric**Improve BP Control: Increase % of Patients with BP <140/<90**

BP = blood pressure; Rx = pharmacotherapy; SMBP = Self-measured BP; SBP = systolic BP

Access AMA MAP™ Resources in Azara DRVS



AMA Resources

[Home](#) » [Population Health Resources](#) » [External Programs](#) » [AMA](#)

American Medical Association (AMA)

Through AMA and Azara Healthcare's collaboration, health care organizations will be able to access AMA MAP BP™ metrics, reports, dashboards and scorecards through Azara DRVS—a centralized, scalable data reporting and analytics platform for population health management and quality improvement. Azara DRVS' detailed analytics allow care teams to access a more comprehensive view of their patient population, including the socio-economic challenges that their patients are experiencing. By combining this functionality with the AMA's evidence-based MAP BP quality improvement program, this may lead to meaningful improvement in clinical outcomes over time, improve quality scores and has the potential to streamline reimbursement for health care organizations. If you are interested in learning more, additional information can be found at map.ama-assn.org or you can reach an AMA representative at mapbpsupport@ama-assn.org.

Download the AMA MAP BP™ resources below:

Resource
AMA MAP BP™ Overview
AMA MAP BP™ Implementation
AMA MAP BP™ General FAQ
AMA MAP BP™ Azara User Guide
AMA MAP BP™ Medication Treatment Protocol
AMA MAP BP 2023 Webinar Series
AMA MAP™ Learning Series: MAP BP™ Overview

Learn About the AMA MAP™ Hypertension Program



AMA MAP™
Hypertension



MAP@ama-assn.org



azara
USER CONFERENCE
APR 30–MAY 2
BOSTON, MA 2024

Going for the Cup!

Utilizing DRVS for
Improvement in Diabetic
Outcomes



Objectives



FQHCs in West Virginia




Network improvements with DRVS



Pendleton Community Care



Diabetes Quality Project



Project Results



Starting Your Own Project





This Photo by Unknown Author is licensed under CC BY-NC-ND.



West Virginia Landscape

Health of West Virginia Residents

2nd

Highest national prevalence of general health of adults as either **fair or poor**.

26.3%

West Virginia adults considered their health to be either **fair or poor**.

Demographics




92%

Non-Hispanic,
White



88%

Have a high-
school diploma



14%

Adults have a
disability



17%

Live in
poverty

21%

65 years old
and over

23%

Enter
secondary ed

7%

Veterans

\$55,000

Median
Income

Common Barriers



Digital
literacy



Literacy



Food
insecurities




Age




Transportation



West Virginia Health Centers



Azara Use in West Virginia



Optimization



Optimization on **peer learning** projects highlighting FQHC work and **leveraging of Azara**



Share **policies** and **project information** to other FQHC in learning **webinars** and noodlepod **communication**.



P E N D L E T O N
Community Care

Going for the **STANLEY** Cup






P E N D L E T O N
Community Care, Inc.



Pendleton Community
Care, Inc.

Franklin, West Virginia





PENDLETON
Community Care

Demographics



Staffing

2

MDs

9

Mid-levels



Locations

4

School-
based Sites

3

Clinic
Sites

2

Pharmacies

1

Radiology
Site



Patients

5,084

Patients seen in 2023

60%

Chronic Care

10%

Veterans

60%

Medicare / MA

30%

>200% FPL

99.9%

Non-Hispanic, White

In 2022, 0 patients met all
6 diabetes quality measures
out of a cohort of 617 patients with diabetes.



Internal Challenge to Diabetes Care



Diabetic care spread throughout the visits, often missing valuable tests in the calendar year.



Staff knowledge of quality measures and associated workflows



Scheduling barriers



External Challenges to Diabetes Care

Access

- 1 hour to hospital or Wal-Mart
- Food Insecurity
- Low economic area

Patients

- Highest median age in WV
- Reliance on info from family, not medical professionals

Technology

- Lack of cellular or broadband internet
- Low levels of reading and tech literacy



Background on Project

Aim: Improve the **quality outcomes** of type 1/type 2 diabetic patients by **utilizing Azara DRVS** to identify qualified patients for the diabetic incentive project where **10%** of qualified patients will complete all **6 diabetic outcomes** by project end January 2024.



DRVS Tools | Custom Scorecard

- Quick snapshot of measures at a glance
- Set on DRVS homepage for easy access

PCC DIABETES PDSA*

REPORT

PERIOD

2024

RENDERING PROVIDERS

9 selected

FILTER

+ Add Filter

Update

REPORT

CARE GAPS

GROUPING

No Grouping

TARGETS

Primary

Secondary

Not Met

REPORT FORMAT

Scorecard

MEASURE	RESULT	TARGET	NUMERATOR	DENOMINATOR	EXCLUSIONS	
<div>Diabetes Foot Exam (NQF 0056)</div>	30.7%	90.0%	111	362	1	Download
<div>Diabetes: Eye Exam (CMS 131v9)</div>	62.6%	90.0%	229	366	3	Download
<div>Kidney Profile for Patients with Diabetes</div>	19.3%	Not Set	86	445	24	Download
<div>Diabetes LDL Management - LDL Tested (NQF 0064 modified)</div>	54.5%	Not Set	201	369	0	Download

DRVS Tools | Patient Visit Planning Report

- Made this project much easier to plan.
- Sorting by Cohort made it easier to focus only on patients we were trying to target.

10:00 AM

Wednesday, March 27, 2024

Visit Reason: ESTABLISHED 30 wants to discuss weight loss meds

Patient, Name MRN: 123456 DOB: 6/27/1951 (72)	Sex at Birth: F GI: Female SO: straight or heterosexual	Phone: (123) 456-7890 Lang: English	Portal Access: Y Cohorts: *Diabetes PDSA 2023	PCP: HOUSE, GREGORY Payer: BCBS-WV CM: Unassigned
--	--	--	--	--

DIAGNOSES (4)

COPD

DM

HTN-E

HyLip

RISK FACTORS (3)

ASCVD High (26.64)

BMI

TOB

SDOH (2)

EMPLOYMENT

MED/CARE

RAF GAPS DIAGNOSIS CATEGORIES (2)

Diabetes


Lung Diseases and Disorders

ALERT	MESSAGE	DATE	RESULT	OWNER
Colon CA 45+	Overdue	1/3/2023	Negative	
A1c	Due Soon	10/9/2023	5.7	
LDL	Out of Range	10/9/2023	105	
DM Eye Exam No Retinopathy	Overdue	11/15/2019		
Eye	Overdue	11/15/2019		

Demo data

Demo data

DRVS Tools | Dashboards



Staff Communication



P E N D L E T O N
Community Care, Inc.

PCC Diabetes PDSA FAQ's

Who is eligible? Any patient that has a diagnosis of primary diabetes at any time during 2025.

What do we give patients? Patients should be given a packet including an education sheet and goal card at the first visit they are seen. The card should be filled out by clinical staff to include tests already completed in 2025.



What if a patient loses their card? Patients should be given a new card one time with the dates filled out on it.

How do patients get a mug? Patients should be given a mug after completing all activities on the card in 2025, and making a copy of the card for Jamie D (with the patients name on it.)

Can patients get an extra mug? No. Only patients diagnosed with primary diabetes who complete all 6 tests are eligible for one free mug.

What is the timeframe for this PDSA? Patients can complete diabetes tests anytime during 2025. If a service is done outside of PCC patients can provide proof of a service by January 50th, 2024 to be eligible.

Create Patient Education


That reflects YOUR patient demographics

Name: _____

My A1C Goal _____

TESTS	How Often	Date
Foot Exam	Yearly	
Eye Exam	Yearly	
Microalbumin	Yearly	
eGFR	Yearly	
LDL	Yearly	
HbA1C	At Least 2X Per Year	

Notes: _____



PENDLETON
Community Care, Inc.

1

HbA1C

- This test estimates your average blood sugar levels over the past 3 months.
- This is a blood test and can be done with other lab tests
- Depending on your individual results, your provider may recommend this test every 3 months to 6 months.

2

FOOT EXAM

- This exam is done to detect nerve, skin, and vascular foot changes before they become problems.
- This test is best done when wearing easily removeable shoes.
- This test is recommended at least every year.

3

EYE EXAM

- Our nurses use a special camera to take a picture of your eyes for evaluation.
- If you see an eye doctor yearly we will have you sign a release to get test information from them.
- This test is recommended yearly

4

MICROALBUMIN

- This test is used to detect increased levels of a blood protein (albumin) in your urine. This helps find early signs of kidney damage so they can be treated.
- The urine sample needed for this test can be done at an exam or at a lab visit.
- This test is recommended at least yearly

5

eGFR


- This test helps your provider measure your level of kidney function.
- This is a blood test and can be done with other lab tests
- Depending on your individual results, your provider may recommend this test every year.

6


LDL

- This test measures "bad cholesterol" that causes fatty deposits in your arteries which reduces blood flow.
- This is a fasting blood test that can be done with other lab tests
- This test is recommended at least yearly.

2022 vs 2023 Pendleton Diabetic Scorecard



Average WV FQHC vs Pendleton Community Care



End Result

As of February 2024,

250

patients met all 6
diabetes quality
measures!

40%

Of the 617
qualified patients
with diabetes



How you can do a similar project

BEFORE

- Work with Clinical staff and C-Suite to get buy in.
- Understand the current workflow.
- Think of incentives that matter to YOUR patients.
- Document each expected workflow for the project.
- Train as if staff had never heard of quality measures.

DURING

- Monitor progress often and communicate results.
- Look for problems or changes that can be made throughout the project.
- Cheer on your team!
- Check on staff in person, if possible, and informally.
"How's everything going?"

Resources

- [Fast Facts \(wv.gov\)](http://wv.gov)
- [Facts About Hypertension | cdc.gov](http://cdc.gov)
- [U.S. Census Bureau QuickFacts: West Virginia](#)
- [WV TRANSIT – WHERE PUBLIC TRANSIT GOES, WEST VIRGINIA GROWS](#)

Contact

Jessica Dailey Haas, MSN, RN, C-ONQS
Director of Clinical Transformation
West Virginia Primary Care Association
Jessica.haas@wvpca.org
304-544-4281



Jamie DiFalco PCMH CCE
Quality Improvement Coordinator
www.pccnfc.org
jdifalco@pcc-nfc.org
82 Pine Street Franklin, WV 26807
(304)358-2355 Ext.1170



P E N D L E T O N
Community Care, Inc.

Franklin ♥ Pendleton Community Care
Riverton ♥ North Fork Primary Care
Harman ♥ Harman Health Center

Questions?



Achieve, Celebrate, Engage!

ACE'd it? Share your DRVS success story and become an Azara ACE!

Show your organization has used DRVS to **A**chieve measurable results, **C**elebrate improvement in patient health outcomes, and effectively **E**ngage care teams and/or patients. Stories should showcase how DRVS helped your organization overcome a challenge, the tools and solutions used to drive improvement and details of the successes that resulted from your initiatives. ACEs should be able to provide examples that quantify quality improvement, cost savings, operational efficiency or patient health improvement.

Benefits:

- Azara will help tell your story and provide a client-branded version for your use
- Potential to create a 2-4 minute video or hour-long Azara-hosted webinar
- Win Azara swag!




Submit your success story by completing the form [at this link](#) or scan our QR code:

See this year's ACE posters in the Ballroom Foyer!



We Want to Hear From You!

Click on the session from your agenda in the conference app.
Click the stars in the center of your screen to rate and provide feedback.



Quick and Easy



Rate the session and
the speaker(s)



Provide brief
feedback or ideas



Help us continue to
improve

Thanks for attending!

